167 related articles for article (PubMed ID: 38374055)
21. [MUC16: The Novel Target for Tumor Therapy].
Gao R; Lou N; Han X; Shi Y
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
[TBL] [Abstract][Full Text] [Related]
22. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
23. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
Aguilar EN; Sagar S; Murray BR; Rajesh C; Lei EK; Michaud SA; Goodlett DR; Caffrey TC; Grandgenett PM; Swanson B; Brooks TM; Black AR; van Faassen H; Hussack G; Henry KA; Hollingsworth MA; Brooks CL; Radhakrishnan P
Mol Cancer Ther; 2024 Jun; 23(6):836-853. PubMed ID: 38394685
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
Mun SS; Meyerberg J; Peraro L; Korontsvit T; Gardner T; Malviya M; Kyi C; O'Cearbhaill RE; Liu C; Dao T; Scheinberg DA
Cancer Immunol Immunother; 2023 Nov; 72(11):3773-3786. PubMed ID: 37635172
[TBL] [Abstract][Full Text] [Related]
25. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
Matte I; Lane D; Boivin M; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():234. PubMed ID: 24690311
[TBL] [Abstract][Full Text] [Related]
26. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.
Das S; Batra SK
Cancer Res; 2015 Nov; 75(22):4669-74. PubMed ID: 26527287
[TBL] [Abstract][Full Text] [Related]
27. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.
Giamougiannis P; Martin-Hirsch PL; Martin FL
Carcinogenesis; 2021 Apr; 42(3):327-343. PubMed ID: 33608706
[TBL] [Abstract][Full Text] [Related]
28. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
29. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
[TBL] [Abstract][Full Text] [Related]
30. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
[TBL] [Abstract][Full Text] [Related]
31. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
32. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
[TBL] [Abstract][Full Text] [Related]
33. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
Rao TD; Fernández-Tejada A; Axelrod A; Rosales N; Yan X; Thapi S; Wang A; Park KJ; Nemieboka B; Xiang J; Lewis JS; Olvera N; Levine DA; Danishefsky SJ; Spriggs DR
ACS Chem Biol; 2017 Aug; 12(8):2085-2096. PubMed ID: 28617578
[TBL] [Abstract][Full Text] [Related]
34. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.
Argüeso P; Spurr-Michaud S; Russo CL; Tisdale A; Gipson IK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2487-95. PubMed ID: 12766047
[TBL] [Abstract][Full Text] [Related]
35. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
36. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.
Higashi M; Yamada N; Yokoyama S; Kitamoto S; Tabata K; Koriyama C; Batra SK; Yonezawa S
Pathobiology; 2012; 79(2):101-6. PubMed ID: 22286058
[TBL] [Abstract][Full Text] [Related]
37. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
38. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
40. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
